Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

IV-Lab In-vessel implantable smart sensing device for personalised medicine

Coordinator
Fondazione Istituto Italiano Di Tecnologia, Italy
Runs
1 September 2023 to 29 February 2028
Status
Running
EU funding
€4.2m
Total cost
€4.2m
Partners
5 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101115545

What the project is doing

In the project's own words, from its summary on CORDIS.

The IV-Lab project aims at designing and manufacturing a miniaturized sensing device implantable in the blood vessel for monitoring the health status of patients. The micro-sensor-system would implement a body-embedded system with multiple sensing capabilities, targeting hemodynamic and biochemical parameters, once implanted into blood vessels (vein and/or arterial blood vessels) of vulnerable patients with cardiovascular diseases.

The final goal of the proposal aims at responding the main requests from the Pathfinder Heath work program, that is to endow people with unperceivable sensors, which will allow 1. the continuous long-term monitoring of the health status, and 2. the diagnosis and personalized medical intervention. Once in the vessel, the sensor will be completely unobtrusive and capable of continuous monitoring. The implanted system will be connected with (and powered by) external data collection and communication system coupled trough standardized wireless technology (i.e.

NFC), or even simply by a smartphone in case of asynchronous on-demand monitoring. The device will have miniaturized and shape size allowing the placemen inside veins and arteries without impairing the blood flow, and will be provided with multiple different sensors, able to work in a continuous or asynchronous way, depending on the specific use cases. This device will find important applications in the field of cardiovascular disease, in particular in those patients in which the detection of hemodynamic behavior and specific biomarkers could reduce the re-hospitalization and mortality (i.e. heart failure).

Moreover, in perspective, the system will make possible to monitor the development and outcome of different disease, allowing a prompt and tailored treatment.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Istituto Italiano Di TecnologiaGenovaItalyCoordinator
University of StuttgartStuttgartGermanyParticipant
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainParticipant
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI